We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Roquefort Therapeutics Plc | LSE:ROQ | London | Ordinary Share | GB00BMDQ2T15 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.45 | 4.00 | 4.50 | 0.00 | 07:47:40 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Cmp Integrated Sys Design | 200k | -1.75M | -0.0135 | -3.30 | 5.75M |
TIDMROQ
Roquefort Therapeutics PLC
22 September 2023
22 September 2023
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Investor Presentation via Investor Meet Company
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market , announces that CEO Ajan Reginald and Chairman Stephen West will give a live presentation via the Investor Meet Company platform at 10am BST on Wednesday, 27 September 2023. The objective of the presentation will be to provide investors with an update relating to the Company's Interim Results.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and can arrange to meet ROQUEFORT THERAPEUTICS via:
https://www.investormeetcompany.com/roquefort-therapeutics-plc/register-investor
Investors who already follow ROQUEFORT THERAPEUTICS PLC on the Investor Meet Company platform will automatically be invited.
ENDS
Enquiries:
Roquefort Therapeutics plc Stephen West (Chairman) / Ajan +44 (0)20 3918 Reginald (CEO) 8633 Hybridan LLP (Joint Broker) Claire Louise Noyce Optiva Securities Limited (Joint +44 (0)203 764 Broker) 2341 +44 (0)20 3411 Christian Dennis 1881 Buchanan (Public Relations) Ben Romney / Jamie Hooper / George +44 (0)20 7466 Beale 5000
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.
Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.
Roquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:
-- Midkine antibodies with significant in vivo efficacy and toxicology studies; -- Midkine RNA therapeutics with novel anti-cancer gene editing action; -- Midkine mRNA therapeutics with novel anti-cancer approach; -- STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and -- MK cell therapy with direct and NK-mediated anti-cancer action
For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on Twitter.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRAFZGZLGZNGFZM
(END) Dow Jones Newswires
September 22, 2023 06:42 ET (10:42 GMT)
1 Year Roquefort Therapeutics Chart |
1 Month Roquefort Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions